The Achilles’ heel of an aggressive type of leukaemia has been discovered by British scientists.
It opens the door to developing new drugs for a disease that is notoriously difficult to treat.
About 200 people are diagnosed with acute myeloid leukaemia (AML) each year in Scotland. While younger patients have a better outlook, overall less than one in five patients survive for longer than five years after diagnosis. Survival rates are poor.
Now, the protein that fuels it has been identified for the first time. Known as YTHDF2, it triggers and sustains the disease.
However, it is not needed for healthy cells to function, meaning a medication that destroys YTHDF2 would be a potential cure.
AML is a form of cancer that affects blood cells called myeloid cells, which include red blood cells, platelets and certain types of white blood cells. Patients experience uncontrolled growth of immature myeloid cells and do not produce enough healthy blood cells.
Older people are most prone. Standard treatment is chemotherapy. If this fails the only hope is a stem cell or bone marrow transplant.
The finding, published in Cell Stem Cell, could lead to a medication with significantly less harmful side effects than existing chemotherapy.
The aim would be to efficiently eliminate blood cancer cells in AML – without harming healthy ones.
Researchers at Edinburgh University and Queen Mary University of London carried out a series of experiments to understand the role of YTHDF2 in blood cancer.
Tests in blood samples donated by leukaemia patients showed the protein is abundant in cancer cells and tests in mice then found the protein is required to initiate and maintain the disease.
Further trials enabled scientists to determine the biological pathway by which interfering with the function of YTHDF2 selectively kills blood cancer cells. Importantly, they also showed the protein is not needed to support the function of healthy blood stem cells.
These are responsible for the production of all normal blood cells. In fact, blood stem cells were even more active in the absence of YTHDF2.
Professor Donal O’Carroll, of Edinburgh University’s School of Biological Sciences, who co-led the research, said: “The study shows the promise of a novel class of drugs as the basis for cancer and regenerative medicine treatments.”
AML starts in young white blood cells in the bone marrow. It affects about one in 200 men and one in 255 women in the UK at some point in their lives.
Approximately 19,500 new cases occur every year in the US. It is most often diagnosed in older people.
- READ MORE: NHS approve drug to fight child cancer
Symptoms can include fatigue, fever, frequent infections, bruising or bleeding, weight loss, bone and joint pain, breathlessness, a swollen abdomen and pale skin.
The exact cause is unclear but risks include smoking, being overweight, radiation exposure, previous chemotherapy, certain blood disorders and some immune conditions such as rheumatoid arthritis.
Joint study lead Professor Kamil Kranc, of Barts Cancer Institute, Queen Mary University of London, said: “Our work sets the stage for therapeutic targeting of cancer stem cells in leukaemia while enhancing the regenerative capacity of normal blood stem cells.
“We hope this will establish a new paradigm in cancer treatment.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here